Forskolin directly stimulates adenylate cyclase to boost cAMP levels, which in turn can activate protein kinase A, a key player in numerous signaling cascades with the potential to increase PTRH1 activity. Other activators work by altering intracellular ion concentrations, such as Ionomycin, which elevates calcium levels and can affect calcium-dependent kinases and their related pathways. PMA acts as a DAG analog, engaging with protein kinase C, which is involved in phosphorylation events that can lead to PTRH1 activation. Similarly, LY294002 disrupts PI3K/AKT signaling, and PD98059 impedes the MAPK/ERK pathway, both leading to compensatory cellular responses that can upregulate PTRH1 activity.
Rapamycin, by inhibiting mTOR, affects protein synthesis and degradation, potentially impacting PTRH1 expression levels. SB 216763 prevents the phosphorylation of GSK-3 substrates, which can lead to an increase in PTRH1 activity. Agents like 5-Azacytidine and Trichostatin A modulate gene expression by inhibiting DNA methyltransferases and histone deacetylases, respectively, and can lead to enhanced expression of PTRH1. Polyphenols such as Epigallocatechin gallate and Resveratrol interact with various cellular targets and pathways that can result in modulated PTRH1 activity. 1-Hydroxypyridine-2-thione zinc salt is essential for numerous enzymes that could interact with PTRH1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin serves as a calcium ionophore, elevating intracellular calcium levels, which can modulate calcium-dependent signaling pathways associated with PTRH1 activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA acts as a DAG analog, activating protein kinase C (PKC) which is involved in phosphorylation events that can lead to the activation of PTRH1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, disrupting AKT signaling, which can lead to adjustments in cellular responses increasing PTRH1 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway, which can indirectly lead to an upregulation of PTRH1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of protein synthesis and degradation, which can affect PTRH1 expression levels. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB 216763 acts as a GSK-3 inhibitor, preventing phosphorylation of GSK-3 substrates, which can result in the upregulation of PTRH1 activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which can lead to changes in gene expression patterns, including those related to PTRH1 regulation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases, altering chromatin structure and affecting transcription, which can enhance PTRH1 expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenolic compound that can modulate various signaling pathways, influencing PTRH1 activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is another polyphenol that can affect multiple cellular targets and signaling pathways, potentially leading to changes in PTRH1 activity. | ||||||